Covidh Technologies Limited has officially scheduled its Extra-Ordinary General Meeting (EGM) for April 2, 2026, following board decisions made on March 10, 2026. The company formally communicated these decisions to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

EGM Details and Business Agenda

The EGM will be conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM) at 12:00 P.M. on Thursday, April 2, 2026. The meeting will address five key resolutions requiring shareholder approval.

Proposed Name Change and Strategic Shift

The primary agenda item involves changing the company name from "Covidh Technologies Limited" to "iSERA Lifesciences Limited." This strategic decision reflects the company's pivot from technology sector operations to focus on medical and life sciences activities, including healthcare and allied medical businesses.

The board has obtained name reservation approval from the Ministry of Corporate Affairs (MCA). The change requires alteration of the Memorandum of Association and Articles of Association, subject to shareholder approval through special resolution.

Director Appointments

The EGM will vote on appointing four new directors for 5-year terms effective April 2, 2026:

Voting and Compliance Procedures

The remote e-voting period will commence on March 30, 2026 at 09:00 A.M. and conclude on April 1, 2026 at 05:00 P.M. Members whose names appear in the Register of Members as on the cut-off date of March 26, 2026 are eligible to vote electronically.

The company has engaged MUFG Intime India Private Limited (formerly Link Intime India Private Limited) to provide electronic voting facilities. The EGM notice has been dispatched to stock exchanges and will be available on the company website and BSE Limited's website.

Regulatory Compliance

Pursuant to Regulation 45 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, TPK & Co. Chartered Accountants has provided a compliance certificate confirming the company meets all prescribed conditions for the name change. The certificate addresses requirements including the one-year elapsed period since the last name change and alignment with proposed business activities in life sciences and healthcare sectors.

Covidh Technologies Limited has issued a revised disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, correcting an inadvertent error in the target entity name for its proposed acquisition announced on February 23, 2026.

Correction of Target Entity Name

The company clarified that the target entity name was incorrectly mentioned as "iSERA Biological Private Limited" in the original disclosure. The correct name of the target entity is "iSERA Biological Limited." This correction was made to ensure accuracy in regulatory filings and public disclosures.

Transaction Structure Remains Unchanged

The proposed acquisition structure and terms remain identical to the original disclosure. Covidh Technologies Limited will acquire 100% equity shareholding of iSERA Biological Limited through a non-binding Letter of Intent executed on February 23, 2026. Upon successful completion, iSERA Biological Limited will become a wholly owned subsidiary of the company.

Conditions and Regulatory Framework

The proposed acquisition continues to be subject to the same conditions precedent, including execution of definitive agreements, completion of satisfactory due diligence, receipt of necessary regulatory and statutory approvals, and obtaining shareholders' approvals. The non-binding Letter of Intent remains non-binding except for customary provisions relating to confidentiality, exclusivity, governing law, and costs.

Compliance and Future Disclosures

The revised disclosure emphasizes that all other contents of the earlier disclosure remain unchanged, with only the target entity name being corrected. The company reaffirmed its commitment to making further disclosures as required under SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, upon execution of definitive agreements and occurrence of material developments in the transaction process.